Stock Ratings / Health Care / VIR / insiders

MESO (60) ALVO (58) COAG (57) BCRX (78) ⌘ Pro Terminal →

Vir Biotechnology Inc. (VIR) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$11.75 -1.51% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Vir Biotechnology Inc. (VIR) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $2.01B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VIR)Realized 20D OHLCV Swing Band: ±12.5%

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

VIR Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (VIR)

No recent open-market Form 4 cluster sales or emergency dumps flagged on VIR. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VIR)

✓Walkthrough of VIR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

VIR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +14.97%▲ ASCENDING CHANNEL

2026-10-30O $11.63H $11.84L $11.18C $11.75VOL 1.27M

RES: $13.20SUP: $9.27SMA50: $10.94SMA200: $9.52

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VIR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VIR Butterfly Map → + Track VIR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -7.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on VIR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VIR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for VIR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VIR)

Health Care Rank #907 of 1016 ⚔️ MESO vs VIR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VIR vs. MESO, ALVO, COAG, BCRX)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Vir Biotechnology Inc. (VIR) ranks #907 by composite RQD confidence (31/100, grade E) and #264 by equity capitalization ($2.01B). Within this direct 5-issuer industry benchmark cohort, BCRX leads on earnings valuation at 8.3x trailing P/E, while BCRX leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. BCRX currently holds the highest overall quantitative score in the immediate peer group at 78/100 (B+) compared with VIR at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
VIR ACTIVE Vir Biotechnology Inc.	E	31/100	—	96.0%	-35.0%	-1.51%	$2.01B	Benchmark Subject
MESO Mesoblast Limited	C-	60/100	—	—	—	+17.03%	$2.04B	/meso-vs-vir →
ALVO Alvotech	D+	58/100	—	—	—	-1.01%	$1.91B	/alvo-vs-vir →
COAG Hemab Therapeutics Holdings Inc.	D+	57/100	—	—	—	+4.99%	$1.89B	/coag-vs-vir →
BCRX BioCryst Pharmaceuticals Inc.	B+	78/100	8.3x	—	85.0%	+1.79%	$2.18B	/bcrx-vs-vir →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001706431

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Vir Biotechnology Inc. (VIR) reported GAAP revenue of $68.6M (-7.6% vs. FY2024 revenue of $74.2M , and -20.5% cumulative change since FY2023) , GAAP net income of -$438.0M, operating cash flow of -$391.8M, and free cash flow of -$396.6M (+12.6% YoY). On the balance sheet, VIR closed FY2025 with $1.00B in total assets against $0 in total debt (Altman Z-Score: 2.40, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$68.6M	-$438.0M	-$391.8M	-$396.6M	$1.00B	—
FY2024 (FY)	2024-12-31	$74.2M	-$522.0M	-$446.4M	-$453.7M	$1.40B	—
FY2023 (FY)	2023-12-31	$86.2M	-$615.1M	-$778.8M	-$778.8M	—	—

3. VIR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VIR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Vir Biotechnology Inc. (NASDAQ: VIR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $11.75 (-1.51% 1D, market cap $2.01B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, VIR ranks #907 in composite RQD confidence.

How does VIR compare to MESO and ALVO in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), VIR carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, MESO (Mesoblast Limited) holds a C- grade (60/100 RQD, P/E N/A, ROIC —, cap $2.04B) and ALVO (Alvotech) posts a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $1.91B). Among the 5-stock peer group, BCRX leads on earnings multiple (8.3x) while BCRX leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for VIR?

Per VIR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001706431), Vir Biotechnology Inc. generated $68.6M in revenue (-7.6% YoY), -$438.0M in net income, and -$396.6M in free cash flow against $1.00B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is VIR trading relative to its 50-day, 200-day, and 52-week technical levels?

VIR last traded at $11.75 (-1.51% on volume of 1,421,832 shares), positioning the stock +7.40% above its 50-day simple moving average ($10.94) and +23.42% above its 200-day simple moving average ($9.52). Across its 52-week range of $4.82 to $12.19, VIR sits at the 94.0% percentile with a 14-day RSI of 53.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($10.28 to $13.22).

VIR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are VIR insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies VIR leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: VIR RQD Cockpit VIR 12M Forecast VIR Earnings & Move VIR Dividends & DRIP VIR Insiders & 13F VIR Whale Options VIR Profit Sankey VIR News & Why